Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.Total revenues increased 20% year over year, primarily driven by a rise in total net product revenues.Total net product revenue was $1.15 billion, representing a 19% increase. The increase was primarily related to patient demand for Jakafi (ruxolitinib) across all indications and strong uptake of the initial launch of Niktimvo (axatilimab-csfr).Incyte's adjusted earnings were $2.26 per ...